916791-27-0

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromomethyl-4-nitro-benzoic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs. Its antimicrobial and anti-inflammatory activities make it a promising candidate for the treatment of infections and inflammatory conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromomethyl-4-nitro-benzoic acid serves as an intermediate in the production of agrochemicals, leveraging its antimicrobial properties to protect crops from diseases and pests, thereby enhancing agricultural productivity.
Safety Precautions:
It is crucial to handle 3-Bromomethyl-4-nitro-benzoic acid with care due to its potential to cause skin and eye irritation. Additionally, it may have harmful effects if ingested or inhaled, necessitating proper safety measures during its use and storage.

Upstream product

• 3113-71-1 3-methyl-4-nitrobenzoic acid 
• 88071-90-3 3-bromomethyl-4-nitro-benzoic acid methyl ester 

Downstream Products

• 914777-97-2 3-hydroxymethyl-4-nitrobenzoic acid 
• 1413644-28-6 ethyl 3-[[[(8Z)-heptadec-8-en-1-ylcarbamoyl]oxy]methyl]-4-nitrobenzoic acid 
• 1413644-32-2 ethyl 3-[[[(8Z)-heptadec-8-en-1-ylcarbamoyl]oxy]methyl]-4-nitrobenzoate 
• 412317-99-8 3-hydroxymethyl-4-nitrobenzoic acid ethyl ester 

Relevant academic research and scientific papers

SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS

In one aspect, the invention relates to substituted lH-benzo[d][l,2,3]triazol-l-ol analgoues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g. various tumors and cancers, associated with β-catenin/Tcf protein- protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Design, synthesis and identification of novel colchicine-derived immunosuppressant

Synthesis and biological evaluation of various colchicine analogues through the mixed-lymphocyte reaction (MLR), lymphoproliferation, and inhibitory effects on the inflammatory genes are described. In addition, a new series of immunosuppressive agents developed on the structural basis of colchicine, as well as their structure-activity relationships is reported. The most potent analogue 20a exhibited an excellent immunosuppressive activity on in vivo skin-allograft model, which is comparable to that of cyclosporin A.